Alzamend Neuro, Inc. (ALZN)
1.66
-0.02
(-1.19%)
USD |
NASDAQ |
Sep 09, 10:53
Alzamend Neuro Total Liabilities (Quarterly) : 1.346M for April 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| April 30, 2026 | 1.346M |
| January 31, 2026 | 1.857M |
| October 31, 2025 | 0.7175M |
| July 31, 2025 | 0.9833M |
| April 30, 2025 | 0.6348M |
| January 31, 2025 | 0.7259M |
| October 31, 2024 | 1.255M |
| July 31, 2024 | 2.882M |
| April 30, 2024 | 3.226M |
| January 31, 2024 | 5.046M |
| Date | Value |
|---|---|
| October 31, 2023 | 3.666M |
| July 31, 2023 | 2.741M |
| April 30, 2023 | 2.870M |
| January 31, 2023 | 2.642M |
| October 31, 2022 | 1.638M |
| July 31, 2022 | 1.029M |
| April 30, 2022 | 1.165M |
| January 31, 2022 | 0.467M |
| October 31, 2021 | 1.476M |
| July 31, 2021 | 1.473M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.079M |
| Shareholders Equity (Quarterly) | 0.7332M |
| Current Ratio | 1.311 |